amifostine indications/contra

Stem definitionDrug idCAS RN
insecticides, anthelminthics, pesticides etc., phosphorous derivatives 156 20537-88-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • amifostine
  • aminopropylaminoethyl thiophosphate
  • ethiofos
  • gammaphos
  • WR-2721
  • amifostine trihydrate
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
  • Molecular weight: 214.22
  • Formula: C5H15N2O3PS
  • CLOGP: -1.85
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 95.58
  • ALOGS: -1.06
  • ROTB: 7

Drug dosage:

DoseUnitRoute
1.70 g P

Approvals:

DateAgencyCompanyOrphan
Dec. 8, 1995 FDA CLINIGEN HLTHCARE

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pyrexia 407.37 50.31 121 376 80994 3304368
Mucosal inflammation 300.29 50.31 61 436 7922 3377440
Nausea 280.79 50.31 103 394 129542 3255820
Hypotension 271.92 50.31 80 417 49434 3335928
Vomiting 252.80 50.31 87 410 89444 3295918
Chills 204.33 50.31 54 443 21968 3363394
Laryngeal pain 186.70 50.31 32 465 1597 3383765
Dehydration 177.27 50.31 53 444 33596 3351766
Rash generalised 144.87 50.31 35 462 9747 3375615
Pruritus 124.39 50.31 44 453 46789 3338573
Rash 124.16 50.31 49 448 70772 3314590
Rash maculo-papular 123.72 50.31 28 469 5839 3379523
Injection site erythema 106.53 50.31 35 462 29555 3355807
Dermatitis 104.33 50.31 22 475 3288 3382074
Soft tissue disorder 100.10 50.31 15 482 309 3385053
Injection site reaction 86.74 50.31 26 471 16160 3369202
Malaise 86.22 50.31 37 460 65140 3320222
Radiation skin injury 83.64 50.31 13 484 343 3385019
Thrombocytopenia 81.48 50.31 30 467 35238 3350124
Rash papular 80.78 50.31 18 479 3464 3381898
Rash erythematous 80.26 50.31 21 476 7941 3377421
Rash pruritic 77.33 50.31 21 476 9143 3376219
Neutropenia 75.60 50.31 28 469 33358 3352004
Pharyngitis 74.43 50.31 16 481 2604 3382758
Injection site rash 71.60 50.31 18 479 5798 3379564
Sepsis 69.05 50.31 26 471 32347 3353015
Erythema 68.26 50.31 25 472 28785 3356577
Dyspnoea 64.40 50.31 35 462 102899 3282463
Rash macular 61.42 50.31 15 482 4279 3381083
Toxic epidermal necrolysis 60.58 50.31 15 482 4530 3380832

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC V03AF05 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
CHEBI has role CHEBI:50266 prodrug
MeSH PA D020011 Protective Agents
MeSH PA D011837 Radiation-Protective Agents

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Prevention of Xerostomia Secondary to Radiation Therapy indication
Prevention of Cancer Chemotherapy-Induced Renal Impairment indication
Hypocalcemia contraindication 5291005
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Cerebrovascular accident contraindication 230690007 DOID:6713
Transient ischemic attack contraindication 266257000 DOID:224
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Vomiting contraindication 422400008
Nausea contraindication 422587007
Myelodysplastic syndrome off-label use 109995007
Drug-induced mucositis off-label use 403666006
Chemotherapy-induced neutropenia off-label use 425229001
Prevention of Radiation Therapy-Induced Mucositis off-label use
Prevention of Chemotherapy-Induced Neurotoxicity off-label use

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 -0.38 acidic
pKa2 4.67 acidic
pKa3 10.06 Basic
pKa4 8.46 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alkaline phosphatase, tissue-nonspecific isozyme Enzyme WOMBAT-PK
D(3) dopamine receptor GPCR Ki 6.18 DRUG MATRIX
reactive chemical species Reactive chemical species OTHER DRUG LABEL DRUG LABEL

External reference:

scroll-->
IDSource
4020970 VUID
N0000148443 NUI
C0015020 UMLSCUI
D00226 KEGG_DRUG
CHEMBL1006 ChEMBL_ID
2141 PUBCHEM_CID
4126 RXNORM
108823002 SNOMEDCT_US
386923005 SNOMEDCT_US
4164 MMSL
d03868 MMSL
4020970 VANDF
133029 MMSL
N0000148443 NDFRT
N0000007354 NDFRT
005536 NDDF
CHEBI:2636 CHEBI
D004999 MESH_DESCRIPTOR_UI
DB01143 DRUGBANK_ID
M487QF2F4V UNII
112901-68-5 SECONDARY_CAS_RN

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
amifostine HUMAN PRESCRIPTION DRUG LABEL 1 55390-308 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 12 sections
AMIFOSTINE HUMAN PRESCRIPTION DRUG LABEL 1 62756-581 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 11 sections
Ethyol HUMAN PRESCRIPTION DRUG LABEL 1 66220-017 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 12 sections